Drugs / Travoprost
Travoprost
also known as
Travatan · Travatan Z · OTX-TIC · AL-6221 · ENV515-1 · ENV515-3 · ENV515-3-2 · iDose TR · +8 more
Other / unclassified targets PTGFR via activation
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | IDOSE TR | — | 2026-01-27 | fda.gov ↗ |
| Label expansion | US (FDA) | TRAVATAN Z | — | 2010-08-31 | fda.gov ↗ |
| Label expansion | US (FDA) | TRAVATAN | — | 2003-02-13 | fda.gov ↗ |
| Approved | EU (EMA) | Travatan | — | 2001-11-27 | europa.eu ↗ |
| Approved | US (FDA) | TRAVATAN | — | 2001-03-16 | fda.gov ↗ |
Trials 82 · started per year
today
US approved 2001
EU approved 2001
1
2
3
3
2
4
10
8
4
5
7
5
4
1
2
3
4
1
3
1
3
2
2
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04360174 | Apr 2018 → May 2021 | ocular hypertension, open-angle glaucoma | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01845038 | Apr 2013 → Mar 2014 | glaucoma | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01658839 | Jan → Jul 2013 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT06152861 | Nov 2023 → Aug 2024 | ocular hypertension, open-angle glaucoma | Glaukos Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT05335122 | Mar 2022 → Jan 2024 | ocular hypertension, open-angle glaucoma | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06582732 | Mar 2021 → Nov 2023 | ocular hypertension, open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 2 | NCT04615403 | Nov 2020 → Feb 2022 | open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02754596 | Mar 2016 → Aug 2017 | open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02371746 | Jan 2015 → Feb 2019 | glaucoma | Envisia Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01298687 | Feb → Apr 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00637130 | Oct 2007 → Jan 2008 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00527501 | Aug → Dec 2007 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07075718 | Jun 2025 → Mar 2028 expected | glaucoma | Glaukos Corporation | Recruiting | No outcome recorded |
| Phase 329 trials | ||||||
| Phase 3 | NCT07495852 | Feb 2026 → Jun 2028 expected | glaucoma | Glaukos Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT06061718 | Sep 2023 → Mar 2024 | ocular hypertension, open-angle glaucoma | Glaukos Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT03868124 | Sep 2018 → Jun 2022 | ocular hypertension, open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03519386 | Jul 2018 → Apr 2022 | ocular hypertension, open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04061044 | Jul 2018 → Feb 2020 | open-angle glaucoma | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02914509 | Nov 2016 → Mar 2019 | ocular hypertension, open-angle glaucoma | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02390284 | Sep 2015 → Oct 2024 | glaucoma | University of Miami | Terminated | No outcome recorded |
| Phase 3 | NCT01652664 | Sep 2012 → Mar 2014 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01452009 | Nov → Dec 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Withdrawn | No outcome recorded |
| Phase 3 | NCT01453855 | Nov 2011 → Aug 2012 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01168414 | Aug 2010 → Jan 2011 | ocular hypertension, open-angle glaucoma | Ministry of Health, Malaysia | Completed | No outcome recorded |
| Phase 3 | NCT00912054 | Mar 2010 → May 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT00872651 | Jan 2010 → Nov 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00892762 | Jun 2009 → May 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00848536 | Mar 2009 → Jan 2010 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00767481 | Oct 2008 → Feb 2009 | glaucoma, ocular hypertension | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT00761319 | Oct 2008 → Sep 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00690794 | Jul 2008 → May 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00465803 | Mar 2007 → Jan 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00333125 | Apr 2006 → Feb 2007 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00051168 | Jan 2006 → Mar 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00293761 | Jan → May 2006 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00288951 | Oct 2004 → Jun 2005 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00293800 | Jul 2004 → Dec 2005 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00293787 | Jun 2004 → Aug 2005 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00311389 | Jan 2003 → Sep 2004 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00051142 | Feb 2001 → Jun 2004 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00051155 | Jan 2001 → Jul 2004 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00051181 | Jan 2000 → Jun 2003 | chronic closed-angle glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 434 trials | ||||||
| Phase 4 | NCT07228221 | Jan 2026 → Aug 2031 expected | open-angle glaucoma | Jonathon Myers | Recruiting | No outcome recorded |
| Phase 4 | NCT06848946 | Jan 2025 → Aug 2026 overdue | cataract 50 with or without glaucoma, ocular hypertension, open-angle glaucoma | Glaukos Corporation | Recruiting | No outcome recorded |
| Phase 4 | NCT06066645 | Sep 2023 → May 2027 expected | open-angle glaucoma | Glaukos Corporation | Recruiting | No outcome recorded |
| Phase 4 | NCT04577027 | Jan 2021 → Jan 2022 | vitiligo | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT02796560 | Jul 2016 → Sep 2017 | ocular hypertension, open-angle glaucoma | University of Sherbrooke | Completed | No outcome recorded |
| Phase 4 | NCT03966560 | Jan 2014 → Jan 2015 | open-angle glaucoma | Afyon Kocatepe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02003391 | Dec 2013 → May 2015 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01995136 | Sep 2013 → Jun 2014 | low tension glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01664039 | Sep 2012 → Jun 2014 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01510145 | Feb 2012 → May 2013 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01535768 | Feb 2012 → Jun 2018 | glaucoma | Credit Valley EyeCare | Unknown | No outcome recorded |
| Phase 4 | NCT01493427 | Dec 2011 → Feb 2013 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01464424 | Oct 2011 → Jun 2012 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01978015 | Oct 2011 → Jul 2012 | anterior uveitis, cystoid macular edema | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 4 | NCT01230736 | Oct 2010 → Feb 2011 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01159756 | Jul 2010 → Nov 2011 | ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00966940 | Sep 2009 → Mar 2010 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00798759 | Dec 2008 → May 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00798694 | Nov 2008 → Jan 2011 | glaucoma | Wills Eye | Completed | No outcome recorded |
| Phase 4 | NCT00759239 | Sep 2008 → Jan 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00708422 | Jul 2008 → Aug 2009 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00508469 | Oct 2007 → Jan 2010 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00519753 | Aug 2007 → Dec 2008 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00527592 | May 2007 → Aug 2008 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00468988 | May → Jul 2007 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00444665 | May → Aug 2007 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00471068 | Mar 2007 → Aug 2008 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded |
| Phase 4 | NCT00762645 | Feb 2007 → May 2008 | angle-closure glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00763061 | May 2006 → Apr 2008 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00329095 | Dec 2005 → Apr 2006 | glaucoma, ocular hypertension | Robin, Alan L., M.D. | Completed | No outcome recorded |
| Phase 4 | NCT00308945 | Nov 2003 → Feb 2005 | open-angle glaucoma | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT00061503 | Apr 2003 → Mar 2004 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00347802 | — | glaucoma | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00348023 | — | glaucoma | Innovative Medical | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT01711177 | Oct 2012 → Mar 2013 | open-angle glaucoma | University of Montreal | Completed | No outcome recorded |
| — | NCT01491867 | Dec 2011 → Oct 2012 | glaucoma, ocular hypertension | Semmelweis University | Completed | No outcome recorded |
| — | NCT01361841 | Jan 2009 → Jan 2012 | ocular hypertension, open-angle glaucoma | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Unknown | No outcome recorded |
| — | NCT00441181 | Jan → Dec 2008 | neovascular glaucoma | Federal University of São Paulo | Withdrawn | No outcome recorded |
| — | NCT00435058 | Sep 2005 → Apr 2006 | glaucoma | University of Sao Paulo | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04962009 | Sep 2021 → Jul 2022 | ocular hypertension | Mati Therapeutics Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 43 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03965052 Comparator | Apr → Jul 2019 | glaucoma | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT02312544 Comparator | Nov 2014 → Sep 2015 | glaucoma, ocular hypertension | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02140060 Comparator | Jun → Nov 2014 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT01789736 Comparator | Feb → Jun 2013 | ocular hypertension, open-angle glaucoma | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01474135 Comparator | Dec 2011 → Apr 2012 | glaucoma, ocular hypertension | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01312454 Comparator | Jun 2011 → Jan 2012 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded |
| Phase 2 | NCT01254370 Comparator | Nov 2010 → Jun 2011 | eye adnexa disorder, glaucoma, ocular hypertension | Santen SAS | Completed | No outcome recorded |
| Phase 2 | NCT01114893 Comparator | Apr → May 2010 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00670033 Comparator | Apr → Sep 2008 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT01004900 Comparator | Jun 2009 → Mar 2011 | glaucoma | Singapore Eye Research Institute | Unknown | No outcome recorded |
| Phase 3 | NCT00767494 Comparator | Oct 2008 → Feb 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT00672997 Background | May → Dec 2008 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00980473 Comparator | Sep 2007 → Sep 2011 | glaucoma | Singapore National Eye Centre | Unknown | No outcome recorded |
| Phase 427 trials | ||||||
| Phase 4 | NCT03150160 Background | Sep → Dec 2017 | glaucoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02730871 Background | Jun 2016 → Jul 2018 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded |
| Phase 4 | NCT02419508 Background | Aug 2015 → Feb 2018 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT02097719 Comparator | May → Dec 2014 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02105311 Comparator | Mar 2014 → Feb 2016 | — | Prince of Songkla University | Completed | No outcome recorded |
| Phase 4 | NCT01937312 Background | Oct 2013 → May 2014 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01937299 Background | Oct 2013 → Apr 2014 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01881126 Comparator | Jun 2013 → Oct 2014 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02873806 Background | Mar 2013 → Nov 2019 | open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01547598 Comparator | Dec 2011 → Jul 2013 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01443988 Comparator | Sep 2011 → Jan 2017 | open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01444040 Comparator | Sep 2011 → Mar 2019 | open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01263444 Background | Mar 2011 → Apr 2013 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01315574 Comparator | Feb 2011 → Dec 2013 | glaucoma | Massachusetts Eye and Ear Infirmary | Terminated | No outcome recorded |
| Phase 4 | NCT01253902 Comparator | Dec 2010 → Oct 2011 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00981786 Comparator | Aug 2009 → Sep 2010 | glaucoma | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 4 | NCT00887029 Comparator | Jan → Nov 2009 | ocular hypertension, open-angle glaucoma | Ophthalmic Consultants Centres, Canada | Completed | No outcome recorded |
| Phase 4 | NCT02136589 Background | Sep → Dec 2008 | ocular hyperemia | Tokyo University | Completed | No outcome recorded |
| Phase 4 | NCT00705757 Comparator | Mar 2008 → Apr 2011 | glaucoma, hyperpigmentation of the skin | Summa Health System | Completed | No outcome recorded |
| Phase 4 | NCT00539526 Comparator | Sep 2007 → Jul 2008 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00471380 Comparator | Mar 2007 → Oct 2008 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00444184 Comparator | Mar 2007 → Jan 2008 | glaucoma | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 4 | NCT00440011 Comparator | Aug 2006 → Oct 2007 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00758342 Comparator | May 2006 → Mar 2008 | — | Alcon Research | Terminated | No outcome recorded |
| Phase 4 | NCT00372827 Background | Feb 2004 → Jan 2006 | ocular hypertension, open-angle glaucoma, pigment dispersion syndrome | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00847483 Comparator | Jan → Aug 2002 | glaucoma, ocular hypertension | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01655758 Comparator | Jan 2002 → Dec 2003 | ocular hypertension | University of Parma | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05241938 Comparator | Sep 2021 → Dec 2022 | ocular hypertension, open-angle glaucoma | Federal University of Rio Grande do Sul | Unknown | No outcome recorded |
| — | NCT04868175 Comparator | Oct 2019 → Mar 2021 | glaucoma | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT00121147 Background | Sep 2003 → Oct 2005 | exfoliation syndrome, ocular hypertension, open-angle glaucoma | Hermann Eye Center | Completed | No outcome recorded |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 131 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | travoprost | “To evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid compared to Timolol Maleate...” NCT02312544 ↗120“a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs...” NCT01535768 ↗ “To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle...” NCT04360174 ↗ “Travacom(R) is a combination topical ocular agent, containing travoprost and timolol, which lower intraocular pressure (IOP) by complementary mechanisms of action.” NCT01159756 ↗ “Patients were surveyed using the Ocular Surface Disease Index (OSDI) to evaluate OSD symptoms prior to changing to travoprost BAK-free dosed once every evening.” PMID 19668762 ↗ Sep 2008 “Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.” NCT00690794 ↗ “PURPOSE: To assess ocular surface changes in participants using latanoprost with benzalkonium chloride (Xalatan) and travoprost with SofZia (Travatan Z).” PMID 28617732 ↗ Nov 2018 “Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)” NCT01168414 ↗ “Prostaglandin analogue eye drops (latanoprost, bimatoprost or travoprost) will be prescribed” NCT05241938 ↗ “travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily” NCT00912054 ↗ “OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release” NCT01845038 ↗ “Generic name: Travoprost * Distinctive denomination: Bristrio® (PRO-179)” NCT03965052 ↗ “Travoprost Ophthalmic Solution, 0.004% (Travatan), a prostaglandin” NCT00121147 ↗ “TRAVATAN® PQ (Travoprost ophthalmic solution with PQ, 0.004%)” NCT02419508 ↗ “anchored intracameral implant containing travoprost” NCT06061718 ↗ “Travatan (travoprost 40 mg/ml eye drops, solution)” NCT00471068 ↗ “Travoprost (0.004%) 1 drop each eye once daily” NCT00051168 ↗ “TRAVATAN Z® (travoprost 0.004%)” NCT01881126 ↗ “Travoprost, 0.32 mg” NCT04061044 ↗ “Travoprost” NCT01263444 ↗ |
| Known as | AL-6221 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200799 ↗ |
| Known as | ENV515-1 | “ENV515-1 Travoprost XR” NCT02371746 ↗ |
| Known as | ENV515-3 | “ENV515-3 Travoprost XR” NCT02371746 ↗ |
| Known as | ENV515-3-2 | “ENV515-3-2 Travoprost XR” NCT02371746 ↗ |
| Known as | iDose TR | “iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery” NCT06848946 ↗ |
| Known as | Izba | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200799 ↗ |
| Known as | NSC-760366 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200799 ↗ |
| Known as | OTX-TIC | “To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle...” NCT04360174 ↗1“OTX-TIC (travoprost) intracameral implant” NCT05335122 ↗ |
| Known as | OTX-TP | “To evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid compared to Timolol Maleate...” NCT02312544 ↗ |
| Known as | TRAV | “BAK-free travoprost 0.004% (TRAV) and BAK 0.02%-preserved bimatoprost 0.01% (BIM) during late-day time points in patients with open-angle glaucoma or ocular hypertension.” PMID 25432143 ↗ Nov 2014 |
| Known as | Travatan | “Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)” NCT00758342 ↗9“Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution)” NCT00471068 ↗ “Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year” NCT00705757 ↗ “Travoprost Ophthalmic Solution, 0.004% (Travatan), a prostaglandin” NCT00121147 ↗ “Generic name: Travoprost * Distinctive denomination: Travatan®” NCT03965052 ↗ “Travoprost 0.004% Ophthalmic Solution (Travatan)” NCT00763061 ↗ “Drug: Travoprost 0.004% (Travatan)” NCT00762645 ↗ |
| Known as | TRAVATAN PQ (Travoprost ophthalmic solution with PQ, 0.004%) | “TRAVATAN® PQ (Travoprost ophthalmic solution with PQ, 0.004%)” NCT02419508 ↗ |
| Known as | Travatan TM | “Three of these are commonly used in North America: latanoprost (Latanoprost T, Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).” NCT01361841 ↗ |
| Known as | Travatan Z | “PURPOSE: To compare the duration of action of travoprost ophthalmic solution
0.004% (Travatan Z) formulated without benzalkonium chloride (BAK) to travoprost
ophthalmic...” PMID 18414108 ↗ Apr 20085“Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy” NCT00444665 ↗ “dosed with TRAVATAN Z®, XALATAN®, or LUMIGAN®, 1 drop instilled in each eye once daily for 28 days” NCT01937312 ↗ |
| Known as | Travatan(R) Z | “Travatan(R) Z(travoprost ophthalmic solution)” NCT01474135 ↗ |
| Known as | Travoprost component of duotrav | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200799 ↗ |
| Action | Activate | “Travoprost (0.0015% and 0.004%), a highly selective, potent prostaglandin F (FP) receptor agonist” PMID 11589866 ↗ Oct 20011“Prostanoid FP receptor agonist” CHEMBL1200799 ↗ |
| Modality | Other / unclassified | “Travoprost (0.0015% and 0.004%), a highly selective, potent prostaglandin F (FP) receptor agonist” PMID 11589866 ↗ Oct 2001 |
| Route | Topical | “1 drop each eye once daily” NCT00051168 ↗ |
| Target | PTGFR | “Prostanoid FP receptor agonist” CHEMBL1200799 ↗ |